Capdevila J, Krajewska J, Hernando J, Robinson B, et al. Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study. Thyroid 2023 Dec 7. doi: 10.1089/thy.2023.0463.
PMID: 38062732